Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER

Open-label extensions [studies SP516 (NCT00501969) and SP715 (NCT00594386)] of the CLEOPATRA-PD and PREFER studies were conducted to evaluate the safety, tolerability and efficacy of the dopaminergic agonist, rotigotine, over several years of follow-up in patients with advanced Parkinson’s disease (...

Descripción completa

Detalles Bibliográficos
Autores principales: LeWitt, Peter A., Boroojerdi, Babak, Surmann, Erwin, Poewe, Werner
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2012
Materias:
Neurology and Preclinical Neurological Studies - Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687107/
https://www.ncbi.nlm.nih.gov/pubmed/23208198
http://dx.doi.org/10.1007/s00702-012-0925-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687107/
https://www.ncbi.nlm.nih.gov/pubmed/23208198
http://dx.doi.org/10.1007/s00702-012-0925-5

Ejemplares similares